eLearning module: Clinical development
In this expert authored eLearning module, Professor Huub Schellekens looks at the clinical development process of biosimilars, particularly the importance of clinical trials to demonstrate biosimilarity.
This module will take up to 20 minutes to complete. An application for accreditation of this curriculum has been made to EACCME®. To claim your credits, please ensure you complete the evaluation form at the end of the module. Credits are only commensurate with completion of all of the designated modules.
On completion of the eLearning module, you will be able to:
- Explain what is “Totality of Evidence” and why it is important to prove biosimilarity.
- Explain what type of clinical trials are important in the clinical development process of biosimilars and how they contribute to prove biosimilarity.
All medical oncologists, specialist nurses, and allied healthcare professionals working with patients for whom biosimilars may represent a treatment option.